| 40.55 Delayed Data As of Feb 22 |  0.00 / 0.00%Today’s Change | 35.78 Today|||52-Week Range 42.36 | +6.12% Year-to-Date |
| Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates Feb 22 / Zacks.com - Paid Partner Content | Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct Feb 20 / Zacks.com - Paid Partner Content |
| Top Ranked Income Stocks to Buy for February 22nd Feb 22 / Zacks.com - Paid Partner Content | Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo Feb 19 / Zacks.com - Paid Partner Content |
| Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y Feb 21 / Zacks.com - Paid Partner Content | New Strong Buy Stocks for February 19th Feb 19 / Zacks.com - Paid Partner Content |
| Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Feb 21 / Zacks.com - Paid Partner Content | Novartis Positioned to Be World's Top Drug Seller in 2024 Feb 18 / GuruFocus News - Paid Partner Content |
| Merck Gets Priority Review for Keytruda in Third-Line SCLC Feb 21 / Zacks.com - Paid Partner Content | Top Ranked Growth Stocks to Buy for February 15th Feb 15 / Zacks.com - Paid Partner Content |
| Previous close | 40.55 |
| Today’s open | 40.20 |
| Day’s range | 40.15 - 40.66 |
| Volume | 2,279,847 |
| Average volume (3 months) | 3,610,314 |
| Market cap | $102.5B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +3.85% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 41.5 |
| Price/Sales | 2.31 |
| Price/Book | 18.30 |
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | +0.51 | +1.26% |
| SNYSanofi | 0.00 | 0.00% |
| LLYEli Lilly and Co | 0.00 | 0.00% |
| BMYBristol-Myers Squibb | +0.85 | +1.70% |
| Next reporting date | April 24, 2019 |
| EPS forecast (this quarter) | $0.74 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Simon Paul Dingemans |
Corporate headquarters Brentford, Greater London |
